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S U M M A R Y
Objective: This study was conducted to compare the clinical and microbiological characteristics of ﬁrst
and breakthrough neutropenic fever in hematologic malignancy patients after chemotherapy.
Methods: Breakthrough neutropenic fever was any episode of fever, not present initially, that developed
either during antibiotic therapy or within 1 week of discontinuation of therapy. A total of
687 neutropenic fever episodes in 241 patients were observed from April 2003 to March 2014.
Results: Blood cultures revealed 210 causative microorganisms: 199 (94.8%) were bacteria and 11 (5.2%)
were fungi. Gram-negative bacteria predominated in both types of neutropenic episode (ﬁrst 75% (120/
160) vs. breakthrough 56% (18/32)) and the most common pathogen was Escherichia coli. Antibiotic
resistance rates were higher in breakthrough episodes than ﬁrst episodes (piperacillin/tazobactam 6% vs.
31%, p = 0.006; ceftazidime 9% vs. 31%, p = 0.025). Inappropriate empirical antibiotic treatment was also
more frequent (0% vs. 19%, p = 0.001), as was the 30-day mortality rate (4.3% (19/442) vs. 7.9% (19/245),
p = 0.058), although the latter effect was not statistically signiﬁcant.
Conclusion: It is concluded that the epidemiological proﬁle of breakthrough neutropenic fever is
different from that of ﬁrst episode fever. These data reinforce the view that pooled reporting of
neutropenic fever may be misleading, and that clinicians should approach breakthrough fever as a
distinct entity.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Patients with hematologic disease may develop several
episodes of fever and infection during the period of
chemotherapy-induced neutropenia.1,2 Published guidelines
for the management of febrile neutropenia specify risk* Corresponding author. Tel.: +82 31 787 7021; fax: +82 31 787 4052.
E-mail address: khsongmd@gmail.com (K.-H. Song).
1 Current afﬁliation: Department of Internal Medicine, Ewha Womans University
Mokdong Hospital, Seoul, Korea.
http://dx.doi.org/10.1016/j.ijid.2016.01.006
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).stratiﬁcation, investigation, selection, modiﬁcation, and cessation
of initial empirical antibiotic therapy.3–6 They also address
breakthrough fever during broad-spectrum antibiotic therapy
and prolonged neutropenia. However, the basic epidemiological
data on which most guidelines are based do not distinguish
between ﬁrst fever and breakthrough fever.3–6 Only a few surveys
have focused on differences in epidemiological proﬁles between
ﬁrst and breakthrough neutropenic fever episodes.1,2,7,8
This study was conducted to identify differences in the clinical
and microbiological characteristics of ﬁrst and breakthrough
neutropenic fever episodes after chemotherapy in patients with
hematologic diseases.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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2.1. Patients and deﬁnitions
The cases of all patients who underwent chemotherapy for
acute leukemia or hematopoietic stem cell transplantation
between April 2003 and March 2014, at a single tertiary hospital
(Seoul National University Bundang Hospital, Seongnam, Republic
of Korea), were reviewed retrospectively. Patients aged 15 years
with neutropenia after chemotherapy (absolute neutrophil count
<0.5 109 cells/l, or <1.0 109 cells/l with an expectation of a
decrease to <0.5 109 cells/l during the ensuing 48 h)3 and fever (a
single tympanic temperature measurement 38.0 8C)9 were
enrolled.
Breakthrough fever was any instance of fever not present at the
initial episode and that developed either during antibiotic therapy
or within 1 week after discontinuation of therapy.2 Febrile
episodes were categorized as microbiologically documented
infection (MDI), clinically documented infection (CDI), or unex-
plained fever (UF), according to the Immunocompromised Host
Society consensus deﬁnition.10 Febrile episodes related to blood
transfusion, chemotherapy, or the underlying disease itself were
excluded.
The revised deﬁnition of invasive fungal infections proposed by
the European Organization for Research and Treatment of Cancer/
Invasive Fungal Infections Cooperative Group and the National
Institute of Allergy and Infectious Diseases Mycoses Study Group
(EORTC/MSG),11 and the Centers for Disease Control and Preven-
tion/National Healthcare Safety Network (CDC/NHSN) surveillance
deﬁnition of health care-associated infection for infection sites
were used.12 Primary bacteremia was deﬁned as an unknownTable 1




AML 570 (83.0) 
ALL 86 (12.5) 
Biphenotypic 4 (0.6) 
Other 27 (3.9) 
Chemotherapy
Induction 285 (41.5) 
Consolidation 299 (43.5) 
Reinduction 64 (9.3) 
BMT conditioning 39 (5.7) 
Classiﬁcation of infection
MDI 195 (28.4) 
CDI 273 (39.7) 
UF 219 (31.9) 
Primary sites of infectiona 468 (100)a
Abdomen 161 (34.4) 
Primary bacteremia 69 (14.7) 
Lung 62 (13.2) 
Catheter 51 (10.9) 
Perianal site 50 (10.7) 
Skin and soft tissue 36 (7.7) 
Pharyngo-tonsil 16 (3.5) 
Paranasal sinus or ear 10 (2.1) 
Urinary tract 7 (1.5) 
Other (CNS, joint) 6 (1.3) 
Invasive fungal infections 34 (7.3)b
30-day mortality rate 38 (5.5) 
Microorganism isolated 210 
Inappropriate empirical antibiotic treatment 30 (14.3)c
AML, acute myeloid leukemia; ALL, acute lymphoid leukemia; BMT, bone marrow transp
infection; UF, unexplained fever; CNS, central nervous system.
a Number of primary infection sites: MDI and/or CDI.
b Of MDI and/or CDI, proportion of invasive fungal infections.
c The frequency of inappropriate empirical antibiotic administration in cases where source of bacteremia in a neutropenic patient who showed no
other symptoms or signs besides fever.
Empirical antibiotic therapy was deﬁned as initial antibiotics
started within 24 h of fever without identiﬁcation of the causative
microorganism.3 Appropriate antibiotic treatment was deﬁned as
treatment matching the in vitro susceptibility of subsequently
isolated bacteria.8 The following Gram-negative bacteria were
considered to be multidrug-resistant (MDR): (1) MDR strains of
Pseudomonas aeruginosa and Acinetobacter baumannii resistant to
at least three classes of antibiotics: carbapenems, ureidopenicil-
lins, cephalosporins, monobactams, aminoglycosides, and ﬂuor-
oquinolones; (2) extended-spectrum beta-lactamase (ESBL)-
producing Enterobacteriaceae.13
2.2. Statistical analysis
All statistical analyses were performed using IBM SPSS Statistics
version 21.0 software (IBM Corp., Armonk, NY, USA). Descriptive
statistics were used to summarize the baseline characteristics of
patients. Categorical variables were compared by Chi-square tests
or two-tailed Fisher’s exact tests. Two-sided p-values less than
0.05 were considered statistically signiﬁcant.
3. Results
A total of 687 febrile episodes among 241 patients were
identiﬁed. Underlying hematologic diseases were acute myeloid
leukemia (AML) (n = 570 episodes), acute lymphoid leukemia
(n = 86), acute biphenotypic leukemia (n = 4), and other hemato-
logic diseases (n = 27) including multiple myeloma, lymphoma,






355 (80.3) 215 (87.8) 0.015
64 (14.4) 22 (9.0) 0.041
1 (0.2) 3 (1.2) 0.132
22 (5.0) 5 (2.0) 0.066
125 (28.3) 160 (65.3) <0.001
246 (55.7) 53 (21.6) <0.001
41 (9.3) 23 (9.4) 1.000
30 (6.8) 9 (3.7) 0.120
155 (35.1) 40 (16.3) <0.001
142 (32.1) 131 (53.5) <0.001
145 (32.8) 74 (30.2) 0.495
297 (100)a 171 (100)a
105 (35.4) 56 (32.7) 0.614
58 (19.5) 11 (6.4) <0.001
22 (7.4) 40 (23.4) <0.001
28 (9.4) 23 (13.5) 0.217
35 (11.8) 15 (8.8) 0.353
24 (8.1) 12 (7.0) 0.723
11 (3.7) 5 (2.9) 0.795
6 (2.0) 4 (2.3) 1.000
6 (2.0) 1 (0.6) 0.431
2 (0.7) 4 (2.3) 0.197
6 (2.0)b 28 (16.4)b <0.001
19 (4.3) 19 (7.8) 0.058
168 42 <0.001
19 (11.3)c 11 (26.0)c 0.049
lantation; MDI, microbiologically documented infection; CDI, clinically documented
the microorganism was isolated.
E.Y. Nam et al. / International Journal of Infectious Diseases 44 (2016) 4–76underlying disease in breakthrough episodes than in ﬁrst episodes,
and induction chemotherapy was also more common in break-
through episodes.
There were 442 febrile episodes classiﬁed as ﬁrst episodes and
245 classiﬁed as breakthrough episodes. Of the 687 episodes, 195
(28.4%) were classiﬁed as MDIs, 273 (39.7%) as CDIs, and 219
(31.9%) as UF. In the 468 episodes of CDI or MDI, intra-abdominal
infection (161, 34.4%) was the most frequent primary site of
infection, followed by primary bacteremia and the lung. Pneumo-
nia and catheter-related infections were more common in
breakthrough episodes than in ﬁrst episodes, whereas primary
bacteremia was more common in ﬁrst episodes. Invasive fungal
infections (IFIs) (proven or probable) developed more frequently
in breakthrough episodes (16.4% (28/171) vs. 2.0% (6/297),
p < 0.001).
Blood cultures revealed 210 causative microorganisms: 199
(94.8%) were bacteria and 11 (5.2%) were fungi (Table 2). In both
groups, Gram-negative bacteria predominated among the bacterial
infections (75% (126/168) of ﬁrst and 45.2% (19/42) of break-
through episodes) and Escherichia coli was the most common
Gram-negative species (29.1% of ﬁrst and 16.7% of breakthrough
episodes). Streptococcus species were the most common Gram-
positive bacteria in patients with ﬁrst MDIs, while coagulase-
negative staphylococci were most common in breakthrough MDIs.
Fungemia were present as 0.5% (2/442) of ﬁrst MDIs and 3.7% (9/
245) of breakthrough MDIs.
Among Gram-negative MDIs, antibiotic resistance rates were
higher in breakthrough episodes than ﬁrst ones: for piperacillin/
tazobactam, 6% of the causative microorganisms of ﬁrst MDIs were
non-susceptible to piperacillin/tazobactam vs. 31% of break-
through MDIs (p = 0.006); for ceftazidime this was 9% vs. 31%
(p = 0.025) and for gentamicin this was 6% vs. 53% (p < 0.001).
Notably, carbapenem resistance was only encountered in break-
through episodes (0% vs. 19%; p = 0.001). Moreover a similar trend
was observed among the Gram-positive bacteria: oxacillin 45% vs.Table 2









Gram-positive 40 (23.8) 14 (33.3) 0.237
Coagulase-negative staphylococci 9 7 0.022
Methicillin-resistant 6 5 0.046
Staphylococcus aureus 11 1 0.467
Methicillin-resistant 3 0 1.000
Streptococcus species 14 1 0.313
Enterococcus species 2 5 0.004
Ampicillin-resistant 2 3 0.560
Vancomycin-resistant 0 1 0.200
Bacillus species 4 0 0.586
Gram-negative 126 (75.0) 19 (45.2) <0.001
Escherichia coli 49 7 0.120
ESBL-producing 4 1 1.000
Ciproﬂoxacin-resistant 11 3 1.000
Klebsiella species 37 5 0.195
ESBL-producing 4 1 1.000
Ciproﬂoxacin-resistant 5 1 1.000
Pseudomonas aeruginosa 15 3 1.000
Ciproﬂoxacin-resistant 2 2 0.173
Carbapenem-resistant 0 2 0.038
Enterobacter species 14 2 0.744
Othera 11 2 1.000
Fungus 2 (1.2) 9 (21.5) <0.001
Candida species 2 7 <0.001
Trichosporon asahii 0 2 0.039
ESBL; extended-spectrum beta-lactamase.
a Infections with the following: Fusobacterium spp, Aeromonas spp, Bacteroides
spp, Achromobacter spp, Citrobacter spp, Moraxella spp, Serratia spp, Stenotrophomo-
nas spp.71% (p = 0.385), piperacillin 7% vs. 100% (p = 0.012), and vancomy-
cin 0% vs. 7% (p = 0.264). The frequency of MDR Gram-negative
bacteria was higher in breakthrough episodes (11/120, 9% vs. 5/19,
28%, p = 0.037). However, methicillin resistance rates of Staphylo-
coccus aureus and coagulase-negative staphylococci did not differ
between the two groups (45% (9/20) vs. 63% (5/8), p = 0.403).
Inappropriate use of empirical antibiotic treatment was more
frequent in breakthrough episodes than ﬁrst episodes (p = 0.049),
and 30-day mortality also showed a tendency to be higher
(p = 0.058).
4. Discussion
The clinical and microbiological characteristics of ﬁrst and
breakthrough neutropenic fever episodes are described. There
were similarities and differences between them. The abdomen was
the most common primary site of infection in both groups. It is well
known that damage to the mucosal barrier due to chemotherapy
can cause bloodstream infections leading to bacterial transloca-
tion.3 However, primary bacteremia was more common in ﬁrst
episodes, whereas pneumonia and catheter-related infections
were more common in breakthrough episodes. These ﬁndings are
consistent with a previous study by Aslıhan Demirel et al., in which
the respiratory system was found to be the most common primary
site of infection in secondary breakthrough infections.14
In both groups, Gram-negative bacteria were the predominant
cause of bacteremia. However, among the Gram-positive bacterial
and fungal episodes there were higher frequencies of bacteremia in
breakthrough fever than in ﬁrst episodes. Moreover, among the
breakthrough episodes, a higher proportion of the Gram-negative
bacteria were resistant to broad-spectrum antibiotics. As a result,
the proportion of patients receiving inappropriate empirical
antibiotics was higher in breakthrough MDIs than in ﬁrst MDIs.
Overall mortality rates at 30 days after bloodstream infection also
tended to be higher in breakthrough MDIs, and the proportion of
patients receiving induction chemotherapy for underlying hema-
tologic diseases was higher in breakthrough fever episodes than
ﬁrst episodes. As is widely known, induction chemotherapy is
usually more intensive than chemotherapy at other times and this
exposes the patient to a higher risk of infectious complications.
Thus a higher proportion of induction chemotherapy could itself
lead to higher mortality. However, the higher mortality in
secondary breakthrough fever is consistent with previous stud-
ies,7,14 and it is considered that it is probably a characteristic of
breakthrough episodes.
Proven or probable invasive fungal infections were more
frequent among breakthrough episodes, and a similar observation
has been reported by several researchers. Fungi accounted for 48%
of the secondary infections in the study of Akova et al., 24.7% in the
study of Serra et al., and 11% in the study of Aslıhan et al.2,14,15 This
may be explained by the fact that prolonged neutropenia and the
long-term use of broad-spectrum antibiotics are risk factors for
fungal infection. Interestingly, the proportion of Gram-positive
bacteria was higher in breakthrough fever, but the rates of
methicillin resistance were similar in the two groups. This is in
contrast with the situation for MDR Gram-negative bacteria.
Although the reason for the difference was not explained by the
present ﬁndings, awareness of the difference could be helpful
when clinicians select empirical antibiotics.
This study was conducted retrospectively in a single tertiary
hospital in Korea. As a result, the data represent the local
epidemiological properties and clinical characteristics of neutro-
penic fevers. However, the concept of ﬁrst and breakthrough fever
are applicable to other institutions and the data suggest a general
need to characterize the subpopulations of neutropenic fever. In
this study, several factors that could have inﬂuenced outcomes
E.Y. Nam et al. / International Journal of Infectious Diseases 44 (2016) 4–7 7among the neutropenic patients with MDIs (such as severity of
underlying disease, and severity and duration of mucositis) were
not assessed. Thus, the risk factors for mortality due to neutropenic
fever and the corresponding differences between the two groups
could not be identiﬁed.
In conclusion, the epidemiological proﬁle of breakthrough
neutropenic fever is different from that of ﬁrst episode fever. These
data reinforce the view that pooled reporting of neutropenic fever
could be misleading and that clinicians should approach break-
through fever as distinct from ﬁrst episode fever.
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